Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

A case of erectile dysfunction and risk factors for coronary artery disease

Abstract

The hypothetical case of a man with erectile dysfunction and multiple cardiovascular risk factors is presented to illustrate the use of the second Princeton Consensus Conference Guidelines. Methods to optimize efficacy of the phosphodiesterase inhibitors are described. The overall cardiovascular safety of the phosphodiesterase inhibitors and their interaction with organic nitrates and alpha blockers are discussed.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of Massachusetts male aging study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  2. Feldman HA et al. Erectile dysfunction and coronary risk factors: prospective results from Massachusetts male aging study. Prev Med 2000; 30: 328–338.

    Article  CAS  Google Scholar 

  3. Kloner RA, Jarow JP . Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576–582.

    Article  CAS  Google Scholar 

  4. Fung MM, Bettencourt R, Barrett-Connor E . Heart disease risk factors predict erectile dysfunction 25 y later. The Rancho Bernardo study. J Am Coll Cardiol 2004; 43: 1405–1411.

    Article  Google Scholar 

  5. Kaiser DR et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179–184.

    Article  Google Scholar 

  6. Solomon H, Man JW, Jackson G . Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251–253.

    Article  CAS  Google Scholar 

  7. Grimm Jr RH et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of mild hypertension study (TOMHS). Hypertension 1997; 29: 8–14.

    Article  CAS  Google Scholar 

  8. Wassertheil-Smoller S et al. Effects of antihypertensives on sexual function and quality of life. The TAIM Study. Ann Intern Med 1991; 114: 613–620.

    Article  CAS  Google Scholar 

  9. Llisterri JL et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–341.

    Article  CAS  Google Scholar 

  10. Kostis JB et al. Sexual dysfunction and cardiac risk: the 2nd princeton consensus conference. Am J Cardiol 2005; 96: 313–321.

    Article  Google Scholar 

  11. DeBusk R et al. Management of sexual dysfunction in patients with cardiovascular disease: The princeton consensus panel. Am J Cardiol 2000; 86: 175–181.

    Article  CAS  Google Scholar 

  12. Derby CA et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302–306.

    Article  CAS  Google Scholar 

  13. Pourmand G et al. Do cigarette smokers with erectile dysfunction benefit from stopping? A prospective study. BJU Int 2004; 94: 1310–1313.

    Article  Google Scholar 

  14. Rosen RC, Kostis JB . Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92: 9M–18M.

    Article  CAS  Google Scholar 

  15. Kloner RA . Cardiovascular effects of the three phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149–3155.

    Article  Google Scholar 

  16. Cheitlin MD et al. Use of sildenafil in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273–282.

    Article  CAS  Google Scholar 

  17. Webb DJ et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Card 1999; 83: 21C–28C.

    Article  CAS  Google Scholar 

  18. Webb DJ et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36: 25–31.

    Article  CAS  Google Scholar 

  19. Kloner RA et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42: 1855–1860.

    Article  CAS  Google Scholar 

  20. Kloner RA . Commentary on ‘Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. J Sex Med 2005; 2: 424–425.

    Google Scholar 

  21. DeBusk RF . Sexual activity in patients with angina. JAMA 2003; 290: 3129–3132.

    Article  CAS  Google Scholar 

  22. Sildenafil prescribing information. Pfizer. NY, NY, 2004.

  23. Product Monograph for Levitra® (vardenafil HCL). Bayer Health Care, Glaxo SmithKline, 2003.

  24. Cialis (tadalafil) prescribing information, Lilly ICOS LLC, Indianapolis, Indiana and Bothell: Washington, DC 2003.

  25. Kloner RA, Mitchell M, Emmick JT . Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92: 37M–46M.

    Article  CAS  Google Scholar 

  26. Padma-Nathan H . Sildenafil citrate (Viagra) and erectile dysfunction: a comprehensive four year update on efficacy, safety, and management options. Urology 2002; 60 (Suppl): 1–90.

    Article  Google Scholar 

  27. Mittleman MA, Glasser DB, Orazem J . Clinical trials of sildenafil citrate (Viagra®) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clinic Pract 2003; 57: 597–600.

    CAS  Google Scholar 

  28. Kloner RA et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE5 inhibitor in patients with erectile dysfunction: analysis of five-controlled clinical trials. Pharmacol Ther 2002; 22: 1371.

    Google Scholar 

  29. Kloner RA, Mitchell M, Emmick JT . Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92 (Suppl): 37M–346M.

    Article  CAS  Google Scholar 

  30. Shakir SAW et al. Cardiovascular events in users of sildenafil. Results from first phase of prescription event monitoring in England. BMJ 2001; 322: 651–652.

    Article  CAS  Google Scholar 

  31. Boshier A, Wilton LV, Shakir SAW . Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004; 93: 796–801.

    Article  CAS  Google Scholar 

  32. Wysowski DK, Farinas E, Swartz L . Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331–1334.

    Article  CAS  Google Scholar 

  33. Fox KM, et al., on behalf of the CAESAR 1 (Clinical American and European Studies of Angina And Revascularization) Investigators. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003; 24: 2206–2212.

    Article  CAS  Google Scholar 

  34. Arruda-Olson AM et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287: 719–725.

    Article  CAS  Google Scholar 

  35. Thadani U et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006–2012.

    Article  CAS  Google Scholar 

  36. Patterson D et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation 2002; 106 (Suppl II): II–330.

  37. Hermann HC et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–1626.

    Article  Google Scholar 

  38. Morganroth J et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004; 93: 1378–1383.

    Article  CAS  Google Scholar 

  39. Jackson G et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C–20C.

    Article  CAS  Google Scholar 

  40. Zusman RM et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C–44C.

    Article  CAS  Google Scholar 

  41. Emmick JT, Stuewe SR, Mitchell M . Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 2002; 4 (Suppl H): H32–H47.

    Article  CAS  Google Scholar 

  42. Kloner RA et al. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled trials. J Am Coll Cardiol 2003; 41 (Suppl A): 276A–277A.

    Article  Google Scholar 

  43. Zusman RM, Prisant LM, Brown MJ . Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000; 18: 1865–1869.

    Article  CAS  Google Scholar 

  44. Kloner RA, et al., for the Sildenafil Study Group. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70–73.

    Article  CAS  Google Scholar 

  45. Pickering TG et al. Safety of Viagra (Sildenafil Citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatments. American J Hypertension 2002; 15 (Suppl 1): A55–A56.

    Article  Google Scholar 

  46. Padma-Nathan H et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Presented at the American Society of Hypertension 17th Annual Scientific Meeting. New York, NY, 2002.

  47. Rohde G, Jordan P . Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. (abstr.). Pharmacotherapy 2002; 202: 418.

    Google Scholar 

  48. Kloner RA, Mitchell M, Emmick JT . Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92 (Suppl): 47M–57M.

    Article  CAS  Google Scholar 

  49. Kloner RA et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and the two alpha blockers: doxazosin, and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935–1940.

    Article  Google Scholar 

  50. Auerbach S et al. Coadministered vardenafil (for erectile dysfunction) and tamsulosin do not induce hypotension in patients with benign prostatic hypertrophy. Am J Hypertens 2004; 17: 16A.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R A Kloner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kloner, R. A case of erectile dysfunction and risk factors for coronary artery disease. Int J Impot Res 17 (Suppl 1), S7–S11 (2005). https://doi.org/10.1038/sj.ijir.3901423

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901423

Keywords

Search

Quick links